TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03124290

Intervention type: OTHER
Group type: OTHER
Intervention: paced auditory serial addition test (PASAT)
Description: A number between 1 to 9 is called every three seconds through a speaker, and the performer calculates the last two numbers and shouts the answer.

Intervention type: OTHER
Group type: OTHER
Intervention: paced auditory serial addition test (PASAT)
Description: A number between 1 to 9 is called every three seconds through a speaker, and the performer calculates the last two numbers and shouts the answer.
Study: NCT04373629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: attentional modulation
Description: Attentional instructions when viewing faces will be given

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perceptual modulation
Description: Faces will be presented of varying durations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: naturalistic viewing
Description: Faces will be viewed without specific instructions
Study: NCT04071054

Intervention type: DIAGNOSTIC_TEST
Intervention: Carnation Ambulatory Monitor (CAM)
Description: 7-day detection of arrhythmias with Carnation Ambulatory Monitor (CAM)
Study: NCT01913795

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: integrated pest management
Description: integrated pest management and environmental strategy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: integrated pest management
Description: integrated pest management and environmental strategy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: air purifier
Description: air purifiers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: air purifier
Description: air purifiers

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham air purifier
Description: sham air purifiers
Study: NCT01339377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AO-1000
Description: Mixture of 2 weight% ozone in 98 weight% oxygen injected into the nucleus pulposus of a contained herniated disc.
Study: NCT02999451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: snare-assisted POEM
Description: POEM is performed by using a snare which is retracted into the sheath to expose the tip, leaving a 1-2mm length for operation.~1. After submucosal injection, an initial 2-cm mucosal incision is made by a snare in the posterior esophageal wall.~2. A submucosal tunnel from the esophagus to the gastric cardia is created using a snare.~3. Full-thickness myotomy is performed and extended 2-3 cm beyond the esophagogastric junction (EGJ) using a snare.~4. The mucosal incision is closed with endoclips.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: knife-assisted POEM
Description: POEM is performed by using a conventional endoscopic knife.~1. After submucosal injection, an initial 2-cm mucosal incision is made by a knife in the posterior esophageal wall.~2. A submucosal tunnel from the esophagus to the gastric cardia is created using a knife.~3. Full-thickness myotomy is performed and extended 2-3 cm beyond the esophagogastric junction (EGJ) using a knife.~4. The mucosal incision is closed with endoclips.
Study: NCT04039048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cerebellar transcranial direct current stimulation
Description: Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 20 minutes with a 2mA current.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cerebellar transcranial direct current stimulation
Description: Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 30 seconds with a 2mA current.
Study: NCT01507948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged exposure
Description: PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA. PE consists of four components: psychoeducation about PTSD symptoms and the behavioral or cognitive factors maintaining it, a brief breathing retraining that can be used as a stress management tool, prolonged imaginal exposure to the trauma memory both within-session and repeated as homework, and prolonged in vivo exposure to avoided scenarios in patients' day-to-day lives.
Study: NCT04039048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training
Description: Balance training will be performed through the Biodex Balance System for 20 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Balance training
Description: Balance training will be performed through the Biodex Balance System for 20 minutes.
Study: NCT02369718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to 12 Fournier's lists of words
Description: Patients will listen to words from Fournier's lists of words in presence of noise presented at different Signal to Noise Ratio (SNR). 6 disyllable words Fournier's lists are presented to the implantees: SNRs ranged from 0 to 15 decibels (dBs) (0; 3; 6; 9; 12; 15) ; the subjects repeat orally the words. Then microphone is cleaned and, again, 6 Fournier's lists are presented.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Listening to 48 Fournier's lists of words
Description: 48 disyllable Fournier's lists of words are presented to the subjects (6 SNR\*2 coding strategies\*4 dirtying levels) and the subjects repeat orally the words. Dirtying levels will be simulated by sounds effects.
Study: NCT00744172

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopy
Description: laparoscopic hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vaginal
Description: vaginal hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal
Description: abdominal hysterectomy
Study: NCT01561794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro, BAYQ3939)
Description: (1) Community-acquired pneumonia (CAP): 400 mg BID, i.e. every 12 ± 1 hours (For those with Ccr \> 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days.~2) Hospital-acquired pneumonia (HAP): For the patient with Ccr \> 60 mL/min, 400 mg TID, i.e. every 8 ± 1hours for 7 to 14 days For the patient with 30 ≤Ccr ≤60 mL/min, 400 mg BID, i.e. every 12 ± 1hours for 7 to 14 days 3) Secondary infection of chronic respiratory disease 400 mg BID, i.e. every 12 ± 1 hours (For those with of Ccr \> 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days.
Study: NCT00332124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Choline
Description: 900 mg every day until birth of infant

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn oil every day in place of choline
Study: NCT01199120

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: measure of efficacy of omega-3 fatty acids supplement on cognition and academic performance in children attending elementary school.
Study: NCT01071850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study: NCT02128776

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive care medical home
Description: Comprehensive care provided in our High-Risk Children's Clinic as a medical home augmented by measures to prevent serious illness
Study: NCT03961152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PainCoach app
Description: In response to the patient's input of the pain experienced (no pain, bearable pain, unbearable pain, or untenable pain), the app gave advice on pain medication use, exercises/rest and when to call the clinic from day 1 until day 14 after surgery.
Study: NCT01229839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embolization
Description: embolization with lipiodol and polyvinyl alcohol particles (PVA)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embolization
Description: embolization with lipiodol and polyvinyl alcohol particles (PVA)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion of anticancer agent
Description: infusion with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg ) desolved in water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion of mixture of anticancer agent and lipiodol
Description: infusion of mixture of lipiodol and chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water
Study: NCT03987451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide given subcutaneously (s.c., under the skin) once-weekly for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Semaglutide placebo s.c. given once-weekly for 48 weeks
Study: NCT02128776

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care provided in the offices of private pediatricians or our general pediatrics clinic staffed by faculty-supervised residents.
Study: NCT04047485

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity
Description: During T0, T2 and T3, every subject has been evaluated with a Snellen Chart, to measure visual acuity in number of letters (BVCA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity
Description: During T0, T2 and T3, every subject has been evaluated with a Snellen Chart, to measure visual acuity in number of letters (BVCA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity
Description: During T0, T2 and T3, every subject has been evaluated with a Snellen Chart, to measure visual acuity in number of letters (BVCA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity
Description: During T0, T2 and T3, every subject has been evaluated with a Snellen Chart, to measure visual acuity in number of letters (BVCA)

Intervention type: DIAGNOSTIC_TEST
Intervention: CAM (Confusion Assesment Method)
Description: During the first 48 hours of post-op follow-up, any episode of post-operative Delirium is checked and evaluated.

Intervention type: DIAGNOSTIC_TEST
Intervention: CAM (Confusion Assesment Method)
Description: During the first 48 hours of post-op follow-up, any episode of post-operative Delirium is checked and evaluated.
Study: NCT03538002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue-light filtering spectacle lenses
Description: This is a single vision spectacle lens for correction of distant refractions and filtering out the blue light by providing anti-blue light coating.
Study: NCT01802801

Intervention type: OTHER
Intervention: embryo development
Description: intra- and inter-observator analysis
Study: NCT03113071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine will be administered in combination with Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine will be administered in combination with Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Decitabine will be administered in combination with Digoxin
Study: NCT04047485

Intervention type: DIAGNOSTIC_TEST
Intervention: CAM (Confusion Assesment Method)
Description: During the first 48 hours of post-op follow-up, any episode of post-operative Delirium is checked and evaluated.

Intervention type: DIAGNOSTIC_TEST
Intervention: CAM (Confusion Assesment Method)
Description: During the first 48 hours of post-op follow-up, any episode of post-operative Delirium is checked and evaluated.

Intervention type: DIAGNOSTIC_TEST
Intervention: CATQUEST 9-SF
Description: The questionnaire contains questions evaluating the benefits of cataract surgery. The questionnaire has been used during T0, T2 and T3

Intervention type: DIAGNOSTIC_TEST
Intervention: CATQUEST 9-SF
Description: The questionnaire contains questions evaluating the benefits of cataract surgery. The questionnaire has been used during T0, T2 and T3
Study: NCT03113071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Decitabine will be administered in combination with Digoxin
Study: NCT04047485

Intervention type: DIAGNOSTIC_TEST
Intervention: CATQUEST 9-SF
Description: The questionnaire contains questions evaluating the benefits of cataract surgery. The questionnaire has been used during T0, T2 and T3

Intervention type: DIAGNOSTIC_TEST
Intervention: CATQUEST 9-SF
Description: The questionnaire contains questions evaluating the benefits of cataract surgery. The questionnaire has been used during T0, T2 and T3

Intervention type: DIAGNOSTIC_TEST
Intervention: OCT
Description: Using the RNFL and the Macular Topography protocol, the macula and optical nerve are measured during the T2 phase of each patient the risk of Irvine Gas's syndrome or any other retinal complication.

Intervention type: DIAGNOSTIC_TEST
Intervention: OCT
Description: Using the RNFL and the Macular Topography protocol, the macula and optical nerve are measured during the T2 phase of each patient the risk of Irvine Gas's syndrome or any other retinal complication.

Intervention type: DIAGNOSTIC_TEST
Intervention: OCT
Description: Using the RNFL and the Macular Topography protocol, the macula and optical nerve are measured during the T2 phase of each patient the risk of Irvine Gas's syndrome or any other retinal complication.

Intervention type: DIAGNOSTIC_TEST
Intervention: OCT
Description: Using the RNFL and the Macular Topography protocol, the macula and optical nerve are measured during the T2 phase of each patient the risk of Irvine Gas's syndrome or any other retinal complication.

Intervention type: DIAGNOSTIC_TEST
Intervention: 6CIT
Description: This Cognitive Impairment test doesn't require Visual function to be executed. Cognitive function is evaluated at T0, T1 and the post-operative trend at T2 and T3.

Intervention type: DIAGNOSTIC_TEST
Intervention: 6CIT
Description: This Cognitive Impairment test doesn't require Visual function to be executed. Cognitive function is evaluated at T0, T1 and the post-operative trend at T2 and T3.

Intervention type: DIAGNOSTIC_TEST
Intervention: 6CIT
Description: This Cognitive Impairment test doesn't require Visual function to be executed. Cognitive function is evaluated at T0, T1 and the post-operative trend at T2 and T3.

Intervention type: DIAGNOSTIC_TEST
Intervention: 6CIT
Description: This Cognitive Impairment test doesn't require Visual function to be executed. Cognitive function is evaluated at T0, T1 and the post-operative trend at T2 and T3.
Study: NCT00679666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: 01% riboflavin drops for 30 minutes q 3 minutes before and during the procedure with exposure to UVA light for the second 30 minutes

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Drops are given q 3 minutes before (30 minutes) and during the procedure (30 minutes) but without the use of UVA light. No activation of cross linking occurs.
Study: NCT02568774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Acupuncture
Description: Treatment is based on the traditional Chinese medicine theory for treating overactive bladder. Qi-transforming function of bladder is regulated by experienced Chinese medicine practitioner.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
Study: NCT01611155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine
Description: Given PO
Study: NCT04047485

Intervention type: DIAGNOSTIC_TEST
Intervention: Barthel Index
Description: To evaluate the everyday independence of the subject and it's trend durin the follow-up

Intervention type: DIAGNOSTIC_TEST
Intervention: Barthel Index
Description: To evaluate the everyday independence of the subject and it's trend durin the follow-up

Intervention type: DIAGNOSTIC_TEST
Intervention: Barthel Index
Description: To evaluate the everyday independence of the subject and it's trend durin the follow-up

Intervention type: DIAGNOSTIC_TEST
Intervention: Barthel Index
Description: To evaluate the everyday independence of the subject and it's trend durin the follow-up

Intervention type: DIAGNOSTIC_TEST
Intervention: Endothelial Microscopy - Cornea
Description: Endothelial cell density is evaluated before surgery (T0) and during the follow-up (T2 and T3). The reason of the choice of this test is to evaluate the trend of these instrumental parameters in the elderly population.

Intervention type: DIAGNOSTIC_TEST
Intervention: Endothelial Microscopy - Cornea
Description: Endothelial cell density is evaluated before surgery (T0) and during the follow-up (T2 and T3). The reason of the choice of this test is to evaluate the trend of these instrumental parameters in the elderly population.

Intervention type: DIAGNOSTIC_TEST
Intervention: Endothelial Microscopy - Cornea
Description: Endothelial cell density is evaluated before surgery (T0) and during the follow-up (T2 and T3). The reason of the choice of this test is to evaluate the trend of these instrumental parameters in the elderly population.

Intervention type: DIAGNOSTIC_TEST
Intervention: Endothelial Microscopy - Cornea
Description: Endothelial cell density is evaluated before surgery (T0) and during the follow-up (T2 and T3). The reason of the choice of this test is to evaluate the trend of these instrumental parameters in the elderly population.
Study: NCT01611155

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT02021773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBR-101 High Dose
Description: Subcutaneously Administered LBR-101 Monthly x 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBR-101 Low Dose
Description: Subcutaneously Administered LBR-101 Monthly x 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously Administered Placebo (Vehicle) Monthly x 3
Study: NCT02903836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafithromycin 800 mg 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafithromycin 800 mg 5 days
Study: NCT00517790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869 .25 mg/kg
Description: Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869 0.10 mg/kg
Description: Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
Study: NCT04658485

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of the primary motor cortex (M1) with the cathode located over the right primary somatosensory cortex (S1).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide a sham stimulation with the anode place over the primary motor cortex (M1) and cathode located over the right primary somatosensory cortex (S1). The sham stimulation consists of 30 seconds of stimulation ramping up to a maximum of 2 mA, then 19 minutes of the device providing no stimulation and then ramping down from 2 mA intensity to 0 in the last 30 seconds. This configuration is designed to mimic the sensory experience of active tDCS.
Study: NCT01969214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQP-MM-101
Description: Dissolve the effervescent tablets in half a glass of water, to be taken orally~1 tablet, 3 times a day
Study: NCT01459627

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6 months DAPT
Description: Dual antiplatelet therapy will be stopped at randomisation to the 6 months DAPT group. Patients will be treated from 6 months onwards only with ASA.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12 months DAPT
Description: Dual antiplatelet therapy will be continued till 12 months after enrollment in the study
Study: NCT03107845

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Description: Treatments are conducted by cognitive-behavioral therapists in training with different levels of experience as well as licensed cognitive-behavioral therapists with several years of experience. The treatment approach is based on cognitive-behavioral manuals and principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT plus Feedback
Description: Therapists of the IG1 are provided with information about the initial status concerning symptoms (BSI \& OQ-30), interpersonal functioning (IIP-32 \& OQ-30) as well as diagnoses specific symptoms (GAD-7 or PHQ-9). Beside the status measures, also individual progress information on the symptom level (HSCL-11 each session) is provided to the therapist. Randomized controlled trial to evaluate the effects of personalized prediction and adaptation tools on treatment outcome in outpatient psychotherapy. This group is a matched sample.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT plus Feedback plus CST
Description: Additional to the intervention group CBT and Feedback therapists will be provided with additional clinical support tools (CST) which are designed to facilitate treatment selection and treatment adaptation. The causes of deterioration will be assessed and therapists will be provided with additional treatment recommendations and material to help preventing treatment failure for a specific patient. During treatment the clinical support tools will be provided in the problem fields: risk/suicidality, motivation / treatment goals, therapeutic relationship, social support / critical life events, and emotion regulation / self regulation.
Study: NCT04512014

Intervention type: DIAGNOSTIC_TEST
Intervention: serum lactate
Description: perioperative measurement of lactate levels